The stock of Replimune Group Inc (NASDAQ:REPL) last traded at $7.36, up 9.04% from the previous session.
Data from the available sources indicates that Replimune Group Inc (NASDAQ:REPL) is covered by 9 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $48.00 and a low of $10.00, we find $13.00. Given the previous closing price of $6.75, this indicates a potential upside of 92.59 percent. REPL stock price is now -44.61% away from the 50-day moving average and -59.55% away from the 200-day moving average. The market capitalization of the company currently stands at $434.68M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
In total, 0 analysts have assigned it a hold rating, and 8 have given it a buy rating. Brokers who have rated the stock have averaged $17.22 as their price target over the next twelve months.
In other news, Xynos Konstantinos, Chief Medical Officer sold 7,313 shares of the company’s stock on Nov 16. The stock was sold for $79,858 at an average price of $10.92. Upon completion of the transaction, the Chief Medical Officer now directly owns 112,714 shares in the company, valued at $0.83 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 16, Chief Commercial Officer Sarchi Christopher sold 5,255 shares of the business’s stock. A total of $57,385 was realized by selling the stock at an average price of $10.92. This leaves the insider owning 72,245 shares of the company worth $0.53 million. Insiders disposed of 174,192 shares of company stock worth roughly $1.28 million over the past 1 year. A total of 26.61% of the company’s stock is owned by insiders.
With an opening price of $6.80 on Wednesday morning, Replimune Group Inc (NASDAQ: REPL) set off the trading day. During the past 12 months, Replimune Group Inc has had a low of $5.89 and a high of $29.52. As of last week, the company has a debt-to-equity ratio of 0.13, a current ratio of 12.76, and a quick ratio of 12.76. The fifty day moving average price for REPL is $13.29 and a two-hundred day moving average price translates $18.20 for the stock.
The latest earnings results from Replimune Group Inc (NASDAQ: REPL) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.9, missing analysts’ expectations of -$0.86 by -0.04. This compares to -$0.79 EPS in the same period last year. The company reported revenue of $63.83 million for the quarter, compared to $41.58 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 53.52 percent.
